Biotech Brief
FDA approvals and big pharma M&A underscore biotech late-stage momentum
Several developments point to late-stage execution strengthening across the biotech sector: FDA approvals of Merck’s oral PCSK9 (described as a first) and Celcuity’s first approved breast cancer drug indicate regulatory momentum for differentiated modalities. In parallel, Merck’s ADC in a China lung cancer study is framed as proof-of-concept for front-line replacement potential.
On the funding and strategy side, large transactions and capital-market activity suggest buyers and investors are reallocating risk toward assets they can scale and commercialize. Eli Lilly’s $2.8B acquisition of psychedelics-focused AtaiBeckley expands its neuroscience pipeline, while Avere’s reverse merger and $2.3B advance oral inflammatory IL-23 drug deal with Hansoh show continued appetite for platform and late-stage pipeline access. However, selective exits—such as J&J stopping an eye disease gene therapy after a key phase 2b readout—remain a reminder that clinical evidence can rapidly reset portfolios.
Overall, executives should track: (1) how FDA approval trends are shaping what “de-risked” looks like, (2) whether acquisition activity concentrates around neuroscience and inflammation, and (3) how capital-market windows (IPOs/blank-check style listings and follow-on funding) are being used to bridge to phase 3 or commercialization.
Top Signals
1. FDA approvals extend differentiation beyond GLP-1s and injectables
Signal strength: Strong
Regulatory validation lowers perceived pathway risk and can accelerate partner/investor confidence for similar mechanisms and development strategies—impacting budgeting, BD targets, and launch planning.
Supporting evidence
- STAT+: FDA approves Merck’s oral PCSK9 drug, a first — STAT Biotech, 2026-07-16. Frames the FDA approval as a “first” for an oral PCSK9, signaling regulatory openness to new delivery/therapy formats.
- STAT+: Celcuity’s breast cancer drug approved, its first — STAT Biotech, 2026-07-15. Reports FDA approval of Celcuity’s first breast cancer drug, reinforcing momentum for platform-enabled oncology differentiation.
- Celcuity gains FDA approval for closely watched breast cancer drug — BioPharma Dive, 2026-07-15. Confirms FDA approval and highlights launch/labeling friction (delay and prescribing information surprises), indicating practical execution risks after approval.
2. Big pharma doubles down on psychedelics and targets portfolio expansion
Signal strength: Strong
Mega-deals reshape competitive landscapes by consolidating promising pipelines and signaling which therapeutic areas are now seen as viable for large-scale investment, affecting partnership strategy and investment focus.
Supporting evidence
- STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley — STAT Biotech, 2026-07-16. Describes Lilly’s $2.8B upfront acquisition to expand its neuroscience pipeline—direct evidence of renewed corporate commitment.
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics — BioPharma Dive, 2026-07-16. Interprets the deal as strong validation of psychedelics research and part of a streak of Lilly buyouts—suggesting sustained strategic direction.
3. Inflammation IL-23 dealmaking and reverse mergers signal pipeline access
Signal strength: Early
Large license/advance structures and reverse mergers indicate a repeatable path to fund and acquire pipeline exposure quickly—useful for forecasting competitive entry, supply of later-stage candidates, and investor appetite.
Supporting evidence
- Avere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal — Fierce Biotech, 2026-07-14. Shows a monetization/funding strategy combining public listing via reverse merger with a major IL-23 drug deal and advance financing.
4. Clinical readouts rapidly reshape portfolios: gene therapy discontinued
Signal strength: Early
Explicit discontinuations following phase 2b readouts highlight evidentiary thresholds that can force fast resource reallocation—relevant for diligence, program forecasting, and partnering risk management.
Supporting evidence
- J&J axes eye disease gene therapy after key phase 2b readout — Fierce Biotech, 2026-07-15. Reports termination of a gene therapy program after reviewing a key phase 2b readout—demonstrating clinical evidence can immediately reset portfolio direction.
5. Phase 2 wins in immune and niche indications intensify phase-3 push
Signal strength: Developing
Positive primary endpoints in phase 2 can accelerate investment decisions and trial design spending for phase 3, affecting competitive timing (who gets to phase 3 first) and likely consolidation interest.
Supporting evidence
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial — Fierce Biotech, 2026-07-16. Primary endpoint success in phase 2 nonsegmental vitiligo clears the way to phase 3, indicating momentum in TYK2-led immunology.
- Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors — Fierce Biotech, 2026-07-13. Describes phase 2 alopecia data supporting a “more durable” alternative framing vs JAK inhibitors, indicating competitive pressure on incumbent classes.
6. Capital markets re-open: more IPO filings and queueing to fund mid-stage
Signal strength: Developing
IPO pipeline indicates investor risk appetite is returning for mid-stage programs, which can accelerate development timelines and increase competitive density for phase 2-to-3 funding.
Supporting evidence
- Braveheart, Attovia join next wave of biotech IPOs — BioPharma Dive, 2026-07-15. States two startups are the third and fourth to outline offerings this month, explicitly tying activity to prior IPO momentum.
- Vogenx joins the IPO queue to fund phase 2-stage metabolic drug — Fierce Biotech, 2026-07-16. Reports joining the Nasdaq queue to fund a phase 2-stage metabolic program, showing IPOs are being used to bridge early efficacy into later trials.
Supporting Stories
- STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals — STAT Biotech
- STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect — STAT Biotech
- STAT+: All eyes on data on Biogen’s tau therapy — STAT Biotech
- AAIC: Roche ‘very interested’ in testing tau for Alzheimer’s despite focus on phase 3-stage amyloid drug — Fierce Biotech
- Merck ADC, in China study, shows potential to replace chemo in lung cancer — BioPharma Dive
- FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in Horses — FDA Press Releases
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals — BioPharma Dive
- Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss — BioPharma Dive
Sources
- STAT+: FDA approves Merck’s oral PCSK9 drug, a first — STAT Biotech
- STAT+: Celcuity’s breast cancer drug approved, its first — STAT Biotech
- Celcuity gains FDA approval for closely watched breast cancer drug — BioPharma Dive
- STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley — STAT Biotech
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics — BioPharma Dive
- Avere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal — Fierce Biotech
- J&J axes eye disease gene therapy after key phase 2b readout — Fierce Biotech
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial — Fierce Biotech
- Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors — Fierce Biotech
- Braveheart, Attovia join next wave of biotech IPOs — BioPharma Dive
- Vogenx joins the IPO queue to fund phase 2-stage metabolic drug — Fierce Biotech
- STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals — STAT Biotech
- STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect — STAT Biotech
- STAT+: All eyes on data on Biogen’s tau therapy — STAT Biotech
- AAIC: Roche ‘very interested’ in testing tau for Alzheimer’s despite focus on phase 3-stage amyloid drug — Fierce Biotech
- Merck ADC, in China study, shows potential to replace chemo in lung cancer — BioPharma Dive
- FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in Horses — FDA Press Releases
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals — BioPharma Dive
- Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss — BioPharma Dive